Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months Tolerabilidade, eventos adversos e aderência ao acetato de glatiramer em 28 pacientes com esclerose múltipla usando a droga continuamente por pelo menos seis meses
AIM: To assess tolerability, adverse events and compliance to treatment with glatiramer acetate in multiple sclerosis. METHOD: Review of patient records and individual interviews. RESULTS: 30 individuals residing in the coastal region of the State of São Paulo who had been in use of glatiramer aceta...
Main Authors: | Ana Patricia Perez Fiore, Yara Dadalti Fragoso |
---|---|
Format: | Article |
Language: | English |
Published: |
Academia Brasileira de Neurologia (ABNEURO)
2005-09-01
|
Series: | Arquivos de Neuro-Psiquiatria |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2005000500002 |
Similar Items
-
Glatiramer Acetate in Treatment of Multiple Sclerosis: A Toolbox of Random Co-Polymers for Targeting Inflammatory Mechanisms of both the Innate and Adaptive Immune System?
by: Thomas Vorup-Jensen, et al.
Published: (2012-11-01) -
Physicochemical and Biological Examination of Two Glatiramer Acetate Products
by: Arthur Komlosh, et al.
Published: (2019-07-01) -
Synthetic Cationic Autoantigen Mimics Glatiramer Acetate Persistence at the Site of Injection and Is Efficacious Against Experimental Autoimmune Encephalomyelitis
by: Jimmy Y. Song, et al.
Published: (2021-01-01) -
Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort
by: Valéria Coelho Santa Rita Pereira, et al.
Published: (2012-10-01) -
A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis
by: Colin J. Ross, et al.
Published: (2017-05-01)